InvestSMART

MGC Pharmaceuticals Ltd (ASX: MXC) - Announcements

Current share price for MXC : $0.420 0.01 (2.44%)+

ASX company news and announcements for MGC Pharmaceuticals Ltd (MXC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All MGC Pharmaceuticals Ltd (MXC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than MGC Pharmaceuticals Ltd (MXC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for MGC Pharmaceuticals Ltd (MXC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$18 Annual Report 2017 12 Oct 2017 5:01PM $0.041 $0.420 risen by 924.39%
$18 Major EU Pharma Supply Agreement Signed with Lenis 3 Oct 2017 10:05AM $0.039 $0.420 risen by 976.92%
$18 Letter from the CEO 20 Sep 2017 10:18AM $0.043 $0.420 risen by 876.74%
$18 Appendix 4E and Audited 2017 Financial Report 30 Aug 2017 8:47AM $0.047 $0.420 risen by 793.62%
$18 RMIT and MGC Pharmaceuticals Sign Strategic Agreement 23 Aug 2017 9:57AM $0.044 $0.420 risen by 854.55%
$18 June Quarterly Activity and Cashflow Report 1 Aug 2017 8:38AM $0.042 $0.420 risen by 900%
$18 Appendix 3Y - Change of Director's Interest Notice 6 Jul 2017 4:07PM $0.048 $0.420 risen by 775%
$18 Botanical Division Update - Europe and Australia 3 Jul 2017 10:27AM $0.047 $0.420 risen by 793.62%
$18 Appendix 3B and Cleansing Statement 30 Jun 2017 2:05PM $0.047 $0.420 risen by 793.62%
$18 Exercise of Options by MXC Board 30 Jun 2017 1:03PM $0.046 $0.420 risen by 813.04%
$18 First European Distribution Deal Signed for API Products 19 Jun 2017 10:18AM $0.048 $0.420 risen by 775%
$18 EU Medical Cannabis License Granted with Strategic Agreement 5 Jun 2017 9:59AM $0.043 $0.420 risen by 876.74%
$18 Trading Halt 1 Jun 2017 9:14AM $0.043 $0.420 risen by 876.74%
$18 Positive MGC Derma Clinical Test Results 22 May 2017 1:03PM $0.056 $0.420 risen by 650%
$18 Strategic Agreement Signed with RMIT 2 May 2017 10:12AM $0.062 $0.420 risen by 577.42%
$18 Trading Halt 1 May 2017 1:52PM $0.062 $0.420 risen by 577.42%
$18 New EU Sales Agreements Signed For MGC Derma 1 May 2017 11:02AM $0.063 $0.420 risen by 566.67%
$18 March Quarterly Activity and Cashflow Report 28 Apr 2017 6:37PM $0.060 $0.420 risen by 600%
$18 Successful MXC First Cannabinoid Production 10 Apr 2017 9:39AM $0.076 $0.420 risen by 452.63%
$18 European API Extraction Facility Completed 5 Apr 2017 12:24AM $0.079 $0.420 risen by 431.65%
$18 Exercise of 6.5c Listed Options - Appendix 3B 3 Apr 2017 5:28PM $0.082 $0.420 risen by 415.34%
$18 CHZ: Chesser Executes Binding Term Seet to Acquire Highly 3 Apr 2017 10:42AM $0.079 $0.420 risen by 431.65%
$18 Investor Presentation - March 2017 27 Mar 2017 10:22AM $0.074 $0.420 risen by 467.57%
$18 Successful Completion of $10m Placement - Appendix 3B 23 Mar 2017 2:37PM $0.069 $0.420 risen by 508.70%
$18 Exercise of Options - Appendix 3B 17 Mar 2017 7:12PM $0.079 $0.420 risen by 431.65%

676 - 700 of 818 results

Page 28 of 33

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.